将Sclerostin的中文名词统一为硬骨抑素的建议
摘要
<正>2019年4月9日安进/UCB公司宣布美国食品药品监督管理局(Food and Drug Adminisration,FDA)批准Sclerostin单克隆抗体Evenity (Romosozumab)上市,用于治疗绝经后女性伴高骨折风险的骨质疏松症。Evenity成为全球首个获批上市的抗Sclerostin单克隆抗体药物,既能促进骨形成,又能减少骨吸收。该药的上市将对未来骨质疏松症的治疗模式带来深远影响。2001年,自硬化性骨化症(sclerosteosis,OMIM#269500)致病基因-SOST和其编码蛋白-Sclerostin发现伊始就受到学术界的关注,并推测可作为未来重
引文
[1] Balemans W,Ebeling M,Patel N,et al. Increased bone density in scleros-teosis is due to the deficiency of a novel secreted protein(SOST)[J]. Hum Mol Genet,2001,10:537-543.
[2]杨立宇,付勤.骨硬化蛋白单克隆抗体治疗骨质疏松新进展[J].中华骨质疏松和骨矿盐疾病杂志,2017,10:179-185.
[3]赵凤仪,王莉.硬骨素在骨生成中的作用[J].中国骨质疏松杂志,2009,15:460-462.
[4] van Buchem FSP,Hadders HN,Hansen JF,et al.Hyperostosis corticalis generalisata:report of seven cases[J]. Am J Med,1962,33:387-397.
[5] Van Hul W,Balemans W,Van Hul E,et al. Van Buchem disease(hyperostosis corticalisgeneralisata)maps to chromosome 17q12-q2 1[J]. Am J Hum Genet,1998,62:391-399.
[6] Wergedal JE,Veskovic K,Hellan M,et al. Patients with Van Buchem disease,an osteosclerotic genetic disease,have elevated bone formation markers,higher bone density,and greater derived polar moment of inertia than normal[J]. J Clin Endocr Metab,2003,88:5778-5783.
[7] Balemans W,Van Den Ende J,Paes-Alves AF,et al.Localization of thegene for sclerosteosis to the van Buchem disease-gene re-gion on chromosome 17q12-q21[J]. Am J Hum Genet,1999,64:1661-1669.
[8] Staehling-Hampton K,Proll S,Paeper BW,et al. A 52-kb deletion in the SOST-MEOX1 intergenic region on17q12-q21 is associated with van Buchem disease in the Dutch population[J]. Am J Med Genet,2002,110:144-152.
[9] Brunkow ME,Gardner JC,Van Ness J,et al. Bone dysplasia sclerosteosis results from loss of the SOST gene product,a novel cystine knot-containing protein[J]. Am J Hum Genet,2001,68:577-589.
[10] Balemans W,Van Hul W. Human genetics of SOST[J]. J Musculoskelet Neuronal Interact,2006,6:355-356.
[11] Kusu N,Laurikkala J,Imanishi M,et al. Sclerostin is a novel secreted osteoclast-derived bone morphogenetic protein antagonist with unique ligand specificity[J]. J Biol Chem,2003,278:24113-24117.
[12] Li X,Zhang Y,Kang H,et al. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling[J].J Biol Chem,2005,280:19883-19887.
[13] Baron R,Rawadi G,Roman-Roman S. Wnt signaling:a key regulator of bone mass[J]. Curr Top Dev Biol,2006,76:103-127.
[14] Canalis E. Wnt signalling in osteoporosis:mechanisms and novel therapeutic approaches[J]. Nat Rev Endocrinol,2013,9:575-583.
[15] Monroe DG,McGee-Lawrence ME,Oursler MJ,et al.Update on Wnt signaling in bone cell biology and bone disease[J]. Gene,2012,492:1-18.
[2]杨立宇,付勤.骨硬化蛋白单克隆抗体治疗骨质疏松新进展[J].中华骨质疏松和骨矿盐疾病杂志,2017,10:179-185.
[3]赵凤仪,王莉.硬骨素在骨生成中的作用[J].中国骨质疏松杂志,2009,15:460-462.
[4] van Buchem FSP,Hadders HN,Hansen JF,et al.Hyperostosis corticalis generalisata:report of seven cases[J]. Am J Med,1962,33:387-397.
[5] Van Hul W,Balemans W,Van Hul E,et al. Van Buchem disease(hyperostosis corticalisgeneralisata)maps to chromosome 17q12-q2 1[J]. Am J Hum Genet,1998,62:391-399.
[6] Wergedal JE,Veskovic K,Hellan M,et al. Patients with Van Buchem disease,an osteosclerotic genetic disease,have elevated bone formation markers,higher bone density,and greater derived polar moment of inertia than normal[J]. J Clin Endocr Metab,2003,88:5778-5783.
[7] Balemans W,Van Den Ende J,Paes-Alves AF,et al.Localization of thegene for sclerosteosis to the van Buchem disease-gene re-gion on chromosome 17q12-q21[J]. Am J Hum Genet,1999,64:1661-1669.
[8] Staehling-Hampton K,Proll S,Paeper BW,et al. A 52-kb deletion in the SOST-MEOX1 intergenic region on17q12-q21 is associated with van Buchem disease in the Dutch population[J]. Am J Med Genet,2002,110:144-152.
[9] Brunkow ME,Gardner JC,Van Ness J,et al. Bone dysplasia sclerosteosis results from loss of the SOST gene product,a novel cystine knot-containing protein[J]. Am J Hum Genet,2001,68:577-589.
[10] Balemans W,Van Hul W. Human genetics of SOST[J]. J Musculoskelet Neuronal Interact,2006,6:355-356.
[11] Kusu N,Laurikkala J,Imanishi M,et al. Sclerostin is a novel secreted osteoclast-derived bone morphogenetic protein antagonist with unique ligand specificity[J]. J Biol Chem,2003,278:24113-24117.
[12] Li X,Zhang Y,Kang H,et al. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling[J].J Biol Chem,2005,280:19883-19887.
[13] Baron R,Rawadi G,Roman-Roman S. Wnt signaling:a key regulator of bone mass[J]. Curr Top Dev Biol,2006,76:103-127.
[14] Canalis E. Wnt signalling in osteoporosis:mechanisms and novel therapeutic approaches[J]. Nat Rev Endocrinol,2013,9:575-583.
[15] Monroe DG,McGee-Lawrence ME,Oursler MJ,et al.Update on Wnt signaling in bone cell biology and bone disease[J]. Gene,2012,492:1-18.